Thalidomide in Treating Patients With Gynecologic Sarcomas

Completed · Phase 2

Conditions studied: Endometrial Cancer, Sarcoma

In brief

RATIONALE: Thalidomide may stop the growth of gynecologic sarcomas by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have recurrent or persistent gynecologic sarcomas.

Key facts

Study ID

NCT00006005

Run by

New York University Cancer Institute

Starts

2000-09-01

Expected to finish

2006-08-01

Last updated by the study team

2013-06-21

Who can join

Age: any. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Cancer Center of Albany Medical Center — Albany, New York, United States
• North Shore University Hospital — Manhasset, New York, United States
• St. Vincent's Comprehensive Cancer Center — New York, New York, United States
• NYU School of Medicine's Kaplan Comprehensive Cancer Center — New York, New York, United States
• St. Luke's-Roosevelt Hospital Center - Roosevelt Division — New York, New York, United States
• New York Weill Cornell Cancer Center at Cornell University — New York, New York, United States
• Mount Sinai School of Medicine — New York, New York, United States
• Albert Einstein Clinical Cancer Center — The Bronx, New York, United States
• New York Medical College — Valhalla, New York, United States
• University of Wisconsin Comprehensive Cancer Center — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.